Business Description
Equillium Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
0FY.Germany0A4D.UKEQ.USA IPO Date
2018-10-18Description
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.81 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.42 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | -7.7 | |||||
| 3-Year FCF Growth Rate | -21.6 | |||||
| 3-Year Book Growth Rate | -15.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.45 | |||||
| 9-Day RSI | 18.6 | |||||
| 14-Day RSI | 24.02 | |||||
| 6-1 Month Momentum % | -56.86 | |||||
| 12-1 Month Momentum % | -67.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.13 | |||||
| Quick Ratio | 3.13 | |||||
| Cash Ratio | 2.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -143.95 | |||||
| ROA % | -104.38 | |||||
| ROIC % | -1008.31 | |||||
| ROC (Joel Greenblatt) % | -4829.8 | |||||
| ROCE % | -123.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.78 | |||||
| Price-to-Tangible-Book | 0.82 | |||||
| EV-to-EBIT | 0.14 | |||||
| EV-to-EBITDA | 0.14 | |||||
| EV-to-FCF | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 0.87 | |||||
| Price-to-Net-Cash | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 720.44 |
How Equillium Inc (FRA:0FY) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.173 | ||
| Beta | -0.57 | ||
| Volatility % | 78.24 | ||
| 14-Day RSI | 24.02 | ||
| 14-Day ATR (€) | 0.027117 | ||
| 20-Day SMA (€) | 0.7828 | ||
| 12-1 Month Momentum % | -67.73 | ||
| 52-Week Range (€) | 0.6075 - 3.04 | ||
| Shares Outstanding (Mil) | 34.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Equillium Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Equillium Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Equillium Inc Frequently Asked Questions
What is Equillium Inc(FRA:0FY)'s stock price today?
The current price of FRA:0FY is €0.63. The 52 week high of FRA:0FY is €3.04 and 52 week low is €0.61.
When is next earnings date of Equillium Inc(FRA:0FY)?
The next earnings date of Equillium Inc(FRA:0FY) is 2023-05-12 Est..
Does Equillium Inc(FRA:0FY) pay dividends? If so, how much?
Equillium Inc(FRA:0FY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
